Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration
Bisphosphonates (BPs) have recently been shown to have direct anti-tumor properties. Systemic treatment with BPs can have multiple adverse effects such as osteonecrosis of the jaw and BP induced bone fracturing and spine instability. While benefits of systemic BP treatments may outweigh risks, local...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-03-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137416301038 |
| _version_ | 1828446273810726912 |
|---|---|
| author | Anas Nooh Yu Ling Zhang Daisuke Sato Derek H. Rosenzweig Sébastien Tabariès Peter Siegel Jake E. Barralet Michael H. Weber |
| author_facet | Anas Nooh Yu Ling Zhang Daisuke Sato Derek H. Rosenzweig Sébastien Tabariès Peter Siegel Jake E. Barralet Michael H. Weber |
| author_sort | Anas Nooh |
| collection | DOAJ |
| description | Bisphosphonates (BPs) have recently been shown to have direct anti-tumor properties. Systemic treatment with BPs can have multiple adverse effects such as osteonecrosis of the jaw and BP induced bone fracturing and spine instability. While benefits of systemic BP treatments may outweigh risks, local treatment with BPs has been explored as an alternate strategy to reduce unwarranted risk. In the present study, we examined whether local delivery of BPs inhibits tumor-induced osteolysis and tumor growth more effectively than systemic treatment in an animal model of tumor-induced bone disease. Following establishment of an intra-tibial model of bone metastases in athymic mice, the experimental group was treated by local administration of zoledronate into the tibial lesion. A comparison of the effect of local versus systemic delivery of zoledronate on the formation of tumor-induced osteolysis was also carried out. A significant increase in mean bone volume/tissue volume % (BV/TV) of the locally treated group (12.30±2.80%) compared to the control group (7.13±1.22%) (P<0.001). Additionally, there was a significant increase in the BV/TV (10.90±1.25%) in the locally treated group compared to the systemically treated group (7.53±0.75%) (P=0.005). These preliminary results suggest that local delivery of BPs outperforms both systemic and control treatments to inhibit tumor-induced osteolysis. |
| first_indexed | 2024-12-10T22:09:50Z |
| format | Article |
| id | doaj.art-9a4a3a5027294bb0b0f9591755438e50 |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-12-10T22:09:50Z |
| publishDate | 2017-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-9a4a3a5027294bb0b0f9591755438e502022-12-22T01:31:39ZengElsevierJournal of Bone Oncology2212-13742017-03-016C81510.1016/j.jbo.2017.01.001Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administrationAnas Nooh0Yu Ling Zhang1Daisuke Sato2Derek H. Rosenzweig3Sébastien Tabariès4Peter Siegel5Jake E. Barralet6Michael H. Weber7Division of Orthopaedic Surgery, Department of Surgery, McGill University, Montreal, Québec, CanadaDivision of Orthopaedic Surgery, Department of Surgery, McGill University, Montreal, Québec, CanadaFaculty of Dentistry, McGill University, 3640, Rue University, Montreal, Québec, Canada H3A 0C7Division of Orthopaedic Surgery, Department of Surgery, McGill University, Montreal, Québec, CanadaGoodman Cancer Research Centre, McGill University, Montréal, Québec, CanadaGoodman Cancer Research Centre, McGill University, Montréal, Québec, CanadaDivision of Orthopaedic Surgery, Department of Surgery, McGill University, Montreal, Québec, CanadaDivision of Orthopaedic Surgery, Department of Surgery, McGill University, Montreal, Québec, CanadaBisphosphonates (BPs) have recently been shown to have direct anti-tumor properties. Systemic treatment with BPs can have multiple adverse effects such as osteonecrosis of the jaw and BP induced bone fracturing and spine instability. While benefits of systemic BP treatments may outweigh risks, local treatment with BPs has been explored as an alternate strategy to reduce unwarranted risk. In the present study, we examined whether local delivery of BPs inhibits tumor-induced osteolysis and tumor growth more effectively than systemic treatment in an animal model of tumor-induced bone disease. Following establishment of an intra-tibial model of bone metastases in athymic mice, the experimental group was treated by local administration of zoledronate into the tibial lesion. A comparison of the effect of local versus systemic delivery of zoledronate on the formation of tumor-induced osteolysis was also carried out. A significant increase in mean bone volume/tissue volume % (BV/TV) of the locally treated group (12.30±2.80%) compared to the control group (7.13±1.22%) (P<0.001). Additionally, there was a significant increase in the BV/TV (10.90±1.25%) in the locally treated group compared to the systemically treated group (7.53±0.75%) (P=0.005). These preliminary results suggest that local delivery of BPs outperforms both systemic and control treatments to inhibit tumor-induced osteolysis.http://www.sciencedirect.com/science/article/pii/S2212137416301038Bone metastasesXenograftBisphosphonatesOsteolysisLocal treatmentCancer pain |
| spellingShingle | Anas Nooh Yu Ling Zhang Daisuke Sato Derek H. Rosenzweig Sébastien Tabariès Peter Siegel Jake E. Barralet Michael H. Weber Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration Journal of Bone Oncology Bone metastases Xenograft Bisphosphonates Osteolysis Local treatment Cancer pain |
| title | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration |
| title_full | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration |
| title_fullStr | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration |
| title_full_unstemmed | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration |
| title_short | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration |
| title_sort | intra tumor delivery of zoledronate mitigates metastasis induced osteolysis superior to systemic administration |
| topic | Bone metastases Xenograft Bisphosphonates Osteolysis Local treatment Cancer pain |
| url | http://www.sciencedirect.com/science/article/pii/S2212137416301038 |
| work_keys_str_mv | AT anasnooh intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT yulingzhang intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT daisukesato intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT derekhrosenzweig intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT sebastientabaries intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT petersiegel intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT jakeebarralet intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration AT michaelhweber intratumordeliveryofzoledronatemitigatesmetastasisinducedosteolysissuperiortosystemicadministration |